| Bioactivity | Pivanex (AN-9), a derivative of Butyric acid, is an orally active HDAC inhibitor. Pivanex down-regulates bcr-abl protein and enhances apoptosis. Pivanex has antimetastic and antiangiogenic properties[1]. | ||||||||||||
| Invitro | Pivanex (100-500 μM) exhibits significant anti-proliferation activity in K562 cells[1].Pivanex (100-500 μM) also enhances apoptosis and caspase activity in K562 cells[1].Pivanex (200 μM) induces enhancement in the G2-M phase, a moderate enhancement in the S phase and a slight reduction in G0-G1 of the cell cycle[1].Pivanex (AN-9) has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines[2]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| Name | Pivanex | ||||||||||||
| CAS | 122110-53-6 | ||||||||||||
| Formula | C10H18O4 | ||||||||||||
| Molar Mass | 202.25 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|